Table 4.
Univariate analysis of time to progression (TTP) and overall survival (OS) using the Cox proportional hazard model
| n | TTP analysis | OS analysis | |||
|---|---|---|---|---|---|
| Hazard ratio (95% CI) | Log-rank P-value |
Hazard ratio (95% CI) | Log-rank P-value | ||
| Baseline characteristics | |||||
| Age† | 37 | 0.984 (0.944-1.02) | 0.429 | 0.996 (0.962-1.03) | 0.819 |
| Sex (male vs. female) | 37 (34 vs. 3) |
0.214 (0.028-1.64) |
0.105 | 0.654 (0.155-2.76) |
0.559 |
| Number of disease sites (1 vs. ≥ 2) |
37 (18 vs. 19) |
1.78 (0.754-4.18) |
0.183 | 1.03 (0.501-2.11) |
0.939 |
| Cirrhosis (no vs. yes) | 35 (23 vs. 12) |
2.22 (0.907-5.41) |
0.0743 | 2.23 (0.975-5.11) |
0.0521 |
| Portal vein thrombosis (no vs. yes) |
37 (18 vs. 19) |
1.3 (0.549-3.1) |
0.547 | 2.00 (0.938-4.27) |
0.0682 |
| Hepatitis B (no vs. yes) | 32 (15 vs. 7) |
1.74 (0.685-4.4) |
0.240 | 1.07 (0.489-2.35) |
0.864 |
| Histological grade (low or medium vs. high) |
33 (22 vs. 11) |
0.756 (0.276-2.07) |
0.586 | 0.78 (0.337-1.81) |
0.561 |
| Child-Pugh class (A vs. B) | 37 (31 vs. 6) |
1.49 (0.428-5.18) |
0.530 | 3.39 (1.34-8.61) |
0.0065* |
| ECOG PS (0 vs. 1) | 37 (19 vs. 18) |
3.21 (1.19-8.63) |
0.0157* | 7.86 (2.78-22.2) |
< 0.0001* |
| CLIP stage (≤ 2 vs. > 2) | 27 (15 vs. 12) |
1.57 (0.490-5.00) |
0.445 | 1.23 (0.54-2.81) |
0.62 |
| Soluble proteins | |||||
| Baseline VEGF-A (ng/mL)† | 37 | 0.041 (0.0006-3.00) |
0.132 | 1.04 (0.056-19.4) |
0.977 |
| Baseline VEGF-C (ng/mL)† | 37 | 0.413 (0.196-0.869) |
0.0165* | 0.683 (0.384-1.21) |
0.190 |
| Baseline sVEGFR-2 (ng/mL)† | 37 | 0.887 (0.699-1.13) |
0.325 | 0.969 (0.803-1.17) |
0.746 |
| Baseline sKIT (ng/mL)† | 37 | 0.996 (0.959-1.04) |
0.853 | 0.997 (0.970-1.02) |
0.804 |
| sVEGFR-2 ratio to baseline at C1D28† | 28 | 0.216 (0.0084-5.54) |
0.353 | 0.049 (0.0027-0.672) |
0.0253* |
Hazard ratio < 1 indicates that risk decreases with increasing value
*Significant at the 0.05 level
†Analyzed as continuous variables
CLIP, Cancer of the Liver Italian Program; ECOG PS, Eastern Cooperative Oncology Group performance status